Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Oncology

Business briefs: Bayer, FDA, Ranbaxy

May 15, 2013

Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations
 

Business briefs: Angelina Jolie, adherence, Sanofi, Teva, AbbVie

May 14, 2013

Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves
 

Business briefs: Sanofi, Allergan, Otsuka, Genmab, NIH, Novartis, DOJ

May 02, 2013

Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling.
 

Patent losses stalk BMS, AZ quarterly results

April 25, 2013

Brass-plated brands Plavix and Seroquel continue to lose luster on the two drug makers' balance sheets.
 

Business Briefs: Docs question Gleevec price, Sanofi pill may delay MS onset

April 25, 2013

Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital.
 

Amgen sales up for the quarter, but biosimilars grab buzz

April 24, 2013

Company revenues were up 5% over last year for the quarter, but much of the Q&A chatter centered around biosimilars.
 

Higher prices keep Lilly's quarter flat; Cymbalta DTC pull-back planned

April 24, 2013

Lilly said sales-force downsizing was the right move considering the current portfolio mix and generics shadow. Management also teased some vague pipeline details.
 

Consumers Must Make Own Choices as Health Guidelines Change

Nancy Hicks April 19, 2013

Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.
 

Pfizer pipeline breast cancer drug gets fast tracked

April 11, 2013

FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs.
 

Oncology lifts Roche's Q1, Lucentis finds new fans

April 11, 2013

Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.
 

Success in emerging markets hinges on broad network

April 03, 2013

Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.
 

Business Briefs: Roche, Sanofi, J&J

March 26, 2013

NICE pans Avastin for ovarian cancer (again), Sanofi wants data innovators
 

Elsevier tool puts editorial imprint on news stream

March 26, 2013

Responsive-design PracticeUpdate absorbs OncologyStat to become a more wide-ranging resource of curated content that spans the medical field, not just the Dutch publisher's media.
 

Business briefs: HRT, HPV, Novo Nordisk

March 18, 2013

Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
 

Dendreon calls in air reinforcements for Provenge

February 25, 2013

Dendreon is readying a $5 million-per-quarter "targeted" DTC advertising campaign as the company seeks to goose sluggish growth in sales of its prostate cancer treatment Provenge.
 

Business briefs: Biogen Idec, Novartis EuroPharm, Genentech

January 24, 2013

Biogen Idec's long-acting, reduced-dose MS drug hits its trial endpoints, Novartis pulls Ruvise marketing review and Genentech scores a new Avastin indication.
 

J&J OTC sales slipped 3% in 2012 worldwide

January 22, 2013

CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.
 

Company news: Boehringer Ingelheim, GlaxoSmithKline

January 14, 2013

Boehringer, Horizon Discovery sign collaboration agreement; GSK files for HGS diabetes therapy
 

Company news: Boehringer, Eli Lilly, Merck

January 07, 2013

Boehringer Ingelheim doubles down on one diabetes treatment, while parting ways on another; and Merck closes the year as a force in the start-up market.
 

Gilead expands its oncology pipeline

December 12, 2012

Gilead's $510 million deal to buy YM Biosciences will bring an experimental bone marrow therapy under its roof.
 

Company news: Janssen, Pfizer, BMS and Boehringer Ingelheim

December 11, 2012

Janssen's prostate cancer pill Zytgia got an OK for use in an earlier line of therapy, and drugmakers Pfizer, Bristol-Myers Squibb and Boehringer Ingelheim released new data on blood thinners Eliquis and Pradaxa.
 

Company news: CVS, LiveStrong

November 13, 2012

CVS banishes some name-brand meds from its PBM formulary; LiveStrong and Amstrong break up.
 

Analysts embrace Lilly cancer candidate

October 15, 2012

Analysts are excited about Lilly's experimental cancer drug, ramucirumab, despite few details.
 

Company news: Celgene

October 15, 2012

The FDA granted an indication for first-line use of Celgene's Abraxane in advanced NSCLC
 

OPDP tells Genentech to pull Tarceva vis aids

October 12, 2012

FDA's objections include overstated efficacy and misleading art.
 

Novartis draws attention to sidelined cancer community

October 03, 2012

Novartis relaunched its AdvancedBreastCancerCommunity.org for patients with advanced breast cancer.
 

Boehringer Ingelheim prepares to launch oncology franchise

October 02, 2012

Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That's about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.
 

Herceptin treatment time scrutinized by researchers

September 24, 2012

A government-funded study looks at whether patients with breast cancer really need 12 months of the treatment.
 

FDA approves new cancer drugs from Pfizer, Medivation/Astellas

September 05, 2012

Pfizer Oncology racked up its third FDA approval of a new drug in 13 months as the agency green lighted leukemia drug Bosulif (bosutinib).
 

GPs harried by reps, oncologists not as much

August 30, 2012

Data show detailing pressure and pharmaceutical rep access are still much higher in primary care than in other specialties.
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising App Approval Clinical Trial Consumer COPD Corporate Reputation Diabetes DTC Earnings Elan FDA Generic Generic Drugs iPad Lymphoma Marketing & Communications Merck Mobile Obesity Patients Regulatory Wellness